<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942251</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <nct_id>NCT02942251</nct_id>
  </id_info>
  <brief_title>Relapse Predicting Model for First Episode Depression</brief_title>
  <acronym>RPM-FED</acronym>
  <official_title>The Study of Relapse Predicting Model for First Episode Depression: Big Data Analysis Based on Clinical Features and Immunochemistry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive depression(MDD) is an severe public mental disorders. The purpose of current
      study is using big data analysis based on clinical features and immunochemistry to
      investigate and establish an relapse predict model for patients with first episode MDD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive depression(MDD) is an severe public mental disorders. The purpose of current
      study is using big data analysis based on clinical features and immunochemistry to
      investigate and establish an relapse predict model for patients with first episode MDD.

      This study includes two steps. Step 1: Big data analysis based on the clinical features and
      immunochemical figures of 30000 patients with first episode MDD will be conducted to
      construct a relapse predict model.

      Step 2: 300 patients with first episode MDD will be recruited in this step. Physicians prefer
      to give corresponding treatment recommendation based on the predictive factors to verify this
      relapse model.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAM-D total score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change from baseline to end of study (EOS) in HAM-D total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>12 months</time_frame>
    <description>The time to new intervention for an emerging mood episode</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Major Depressive Disorders</condition>
  <arm_group>
    <arm_group_label>Clinical features and medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of clinical features and medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psycho-social</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of psycho-social problems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>immunology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of immune disturbance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laboratory abnormality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of Laboratory abnormalities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comorbidity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with physical or mental disorders comorbidities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as usual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical features and medication</intervention_name>
    <description>This group will be suggested to take optimize treatment according to Chinese treatment guidelines.</description>
    <arm_group_label>Clinical features and medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psycho-social</intervention_name>
    <description>This group will be suggested to add on psychotherapy on medical treatment.</description>
    <arm_group_label>Psycho-social</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunology</intervention_name>
    <description>This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.</description>
    <arm_group_label>immunology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory abnormality</intervention_name>
    <description>This group will be suggested to more safety antidepressants.</description>
    <arm_group_label>Laboratory abnormality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comorbidity</intervention_name>
    <description>This group will be suggested to treat their comorbidities as well as treat MDD.</description>
    <arm_group_label>Comorbidity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as usual</intervention_name>
    <description>Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.</description>
    <arm_group_label>Treatment as usual</arm_group_label>
    <other_name>Treatment as usual(TAU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 65 years old;

          -  Han Chinese;

          -  Outpatient and inpatient patients;

          -  Patients met Diagnostic and Statistical Manual of Mental Disorders(DSM-IV-TR) criteria
             of bipolar I or II disorder, currently depressed, ascertained with the Mini
             International Neuropsychiatric Interview (MINI)

          -  Hamilton Depression Scale(HAM-D) total score≥17, HAM-D item 1 (depressed mood)
             score≥2, and Young Mania Rating Scale(YMRS) total score≤10 at baseline;

          -  Written informed consent was given;

          -  Junior high school education and above, with enough audio-visual ability to accomplish
             the visits;

          -  Normally resident in one country and had a residential address, able to follow-up.

        Exclusion Criteria:

          -  Bipolar disorder rapid cycling or mixed episode;

          -  Experienced DSM-IV-TR axis I disorders in the 6 months prior to randomization;

          -  Severe personality disorder, metal retardation, anorexia/bulimia nervosa;

          -  Actively suicide ascertained by research psychiatrist or HAM-D item 3
             score≥3(suicidality);

          -  Female patients who were pregnant, planning to be pregnant or breast feeding;

          -  Severe medical or neurological problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Chen, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Chen, M.D., Ph.D</last_name>
    <phone>021-34773367</phone>
    <email>doctorcj2010@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Huang, Master</last_name>
    <phone>13750892815</phone>
    <email>kittyhj_2000@aliyun.com</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>big data analytics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

